References
- Studd J, Holland E F, Leather A T, Smith R N. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994; 101: 787–91
- Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–33
- , et al. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13: 340–67
- Studd J. Why are estrogens rarely used for treatment of depression in women?. Gynecol Endocrinol 2007; 23: 63–64
- Beral V; Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27
- Studd J. Variations on hormone replacement therapy: an answer to the ‘one dose fits all’ Women's Health Initiative study. Gynecol Endocrinol 2007; 23: 665–71
- Davis S R, Burger H G. The rationale for physiological testosterone replacement in women. Balliere's Clin Endocrinol Metab 1998; 12: 391–405
- Horner E, Fleming J, Studd J. A study of women on long-term hormone replacement therapy and their attitude to suggested cessation. Climacteric 2006; 9: 459–63
- Thunnell L, Milsom I, Schmidt J, Mattson L A. Scientific evidence changes prescribing practice – a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. Br J Obstet Gynaecol 2006; 113: 15–20
- Brincat M, Moniz C J, Studd J, et al. Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985; 92: 256–9
- Brincat M P, Calleja-Agius J, Baron Y M. The skin, carotid and intervertebral disc: making the connection!. Climacteric 2007; 10(Suppl 2)83–87
- Khastgir G, Studd J WW, Holland N, et al. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 2001; 86: 289–95
- Khastgir G, Studd J, Holland N, et al. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporosis Int 2001; 12: 465–70
- Muscat Baron Y, Brincat M P, Galea R, Calleja N. Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures. Climacteric 2007; 10: 314–19
- Banks E, Beral V, Reeves G, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 2004; 291: 2212–20
- Bagger Y Z, Tanko L B, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women has long term preventative effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34: 728–35
- Whitehead M, Farmer R. The Million Women Study – a critique. Endocrine 2004; 24: 187–93
- Manson J E, Hsai J, Johnson K C, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–34
- Anderson G L, Limacher M, Assaf A R, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12
- Canonico M, Plu-Bureau G, Lowe G D, Scarabin P Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Br Med J 2008; 336: 1227–31